Corticosteroids are effective medications. In eczema, psoriasis, or atopic dermatitis, they can reduce inflammation, itching, and redness within days. The problem arises when they are used for too long, at too high a strength, or without a clear discontinuation plan. This article is a guide to stopping corticosteroids safely — step by step, with evidence-based recommendations.
Why you shouldn't stop steroids abruptly
Topical corticosteroids — ointments, creams, and lotions containing steroid active ingredients — work by suppressing the local inflammatory response in the skin. With prolonged use, the skin adapts to their presence: natural anti-inflammatory mechanisms are dampened, blood vessels grow accustomed to the vasoconstrictive effect of steroids, and the production of endogenous cortisol analogues decreases.
If you suddenly stop the corticosteroid, the skin — deprived of its effect — reacts with a rebound response. Inflammation returns more intensely than before. Itching worsens, the skin reddens and cracks. This is not a treatment failure — it is a physiological response to the absence of a substance on which the skin has developed a form of dependence.
A systematic review by Haeck et al., published in the Journal of the American Academy of Dermatology, confirmed that abrupt discontinuation of corticosteroid therapy in atopic dermatitis is associated with a significantly higher risk of rebound flares compared to gradual tapering. [PubMed: 21371772]
Important: This applies especially to moderate and potent corticosteroids (group III–IV in the UK classification, or I–II in the American classification). Mild preparations — group I/hydrocortisone in low concentrations — carry less risk, but gradual withdrawal is still advisable.
What is tapering and how does it work?
Tapering is the medically recommended method for discontinuing corticosteroid treatment. The principle lies in gradually extending the intervals between applications — not reducing the amount of product applied.
Proactive therapy — also called proactive maintenance therapy — is today regarded as the gold standard in the management of atopic dermatitis. After achieving remission, corticosteroids are applied 1–2 times per week to areas where flares typically occur, even when the skin appears healthy. This prevents flares rather than reactively treating them. This approach is supported by guidelines from the American Academy of Dermatology (AAD, 2023), the European Academy of Dermatology and Venereology (EADV, 2022), and the Cochrane review by Schmitt et al. [PubMed: 21901708]
The key is transitioning from daily application to intermittent use — first every other day, then twice weekly, then once weekly — while simultaneously building strong supportive barrier care that can replace steroids during the maintenance phase.
A practical tapering plan
Below is a general framework based on EADV and AAD guidelines for atopic dermatitis and chronic inflammatory dermatoses. Always discuss the specific approach with your dermatologist — an appropriate plan depends on the potency of the steroid, duration of use, and body area treated.
| Phase | Corticosteroid application | Concurrent care | Duration |
|---|---|---|---|
| Acute phase | Once daily (as prescribed) | Emollients twice daily | Until remission (typically 1–2 weeks) |
| Transition phase | Every other day, then twice weekly | Emollients + barrier dermocosmetics daily | 2–4 weeks |
| Proactive maintenance | 1–2× weekly on at-risk areas | Intensive barrier care daily | 3–6 months (depending on severity) |
| Steroid-free maintenance | Discontinued | Premium dermocosmetics as daily routine | Long-term |
Note on fingertip unit (FTU): The correct amount of steroid ointment is the amount squeezed from the tip of the index finger to the first crease. One FTU covers an area equivalent to two adult palms. Using excess does not increase efficacy — it only raises the risk of side effects.
How to support your skin barrier during withdrawal
The skin barrier is the most important success factor when withdrawing from corticosteroids. If you can keep it functional — hydrated, intact, and resistant to irritants — you significantly reduce the likelihood of rebound flares.
Emollients as the foundation
Emollients (moisturising and barrier products) are in this context just as important as corticosteroids themselves. The Cochrane review by van Zuuren et al. (2017) analysed 77 randomised studies and confirmed that regular emollient use statistically significantly reduces the frequency of eczema flares, corticosteroid consumption, and overall symptom severity. [PubMed: 28864822]
The rule is simple: the more emollients you apply, the fewer corticosteroids you need. Daily application 2–3 times per day, especially immediately after showering (within 3 minutes of drying off — the so-called "soak and seal" technique), is the minimum standard.
What to look for in the formula
When choosing barrier care for the steroid-tapering phase, look for these ingredients:
- Ceramides — rebuild the lipid matrix of the stratum corneum; a review by Kono et al. (2021) demonstrated their measurable impact on hydration and barrier function. [PubMed: 34596254]
- Hyaluronic acid — binds water within the skin, reducing transepidermal water loss (TEWL).
- Bisabolol, panthenol — soothe irritated skin without a corticosteroid mechanism.
- Anti-inflammatory natural compounds — e.g. cannabidiol (CBD) interacts with the endocannabinoid system of the skin and demonstrates anti-inflammatory and calming effects; a comprehensive review by Kuzumi et al. (2025) summarises the current clinical data. [PubMed: 41008526]
Avoid products containing fragrance, alcohol, or aggressive preservatives — in the unstable skin during steroid withdrawal, these can trigger a contact reaction.
TSW: When it's more than just a flare-up
In some patients — typically those who have used topical corticosteroids daily for more than 2–3 months, at moderate to high potency, over larger skin areas — what happens upon discontinuation may not simply be a rebound flare of the underlying condition. It may be Topical Steroid Withdrawal (TSW), also known as corticosteroid withdrawal syndrome or Red Skin Syndrome.
TSW differs from eczema by specific symptoms: intense burning (rather than itching), redness that spreads beyond the original affected areas, weeping skin, and sheet-like peeling. In March 2025, a team from the US National Institutes of Health (NIH) published a study that, for the first time, demonstrated a biochemical basis for TSW distinct from eczema — an excess of NAD+ in the mitochondria of skin cells.
If your symptoms during withdrawal more closely match this description than a classic eczema flare, it is essential to consult a dermatologist and raise TSW directly. An accurate diagnosis is the prerequisite for the right treatment. Read more about TSW in our dedicated article here.
The role of dermocosmetics in a steroid-sparing approach
The term steroid-sparing describes an approach aimed at minimising the need for corticosteroids — not abruptly stopping them, but systematically reducing dependence on them through strong supportive care. This is precisely the philosophy behind EPIDERMA®.
The product range featuring the patented Betuldiol® complex — a combination of cannabidiol and birch extract — is formulated to actively support the skin barrier, dampen inflammation without a corticosteroid mechanism, and create conditions under which steroids are simply needed less. The updated European guidelines (EADV, 2025) recommend exactly this individualised approach: corticosteroids as the first line for acute conditions, non-steroidal preparations for long-term maintenance.
For the tapering phase and long-term maintenance, we recommend:
- Eczema Balm 300 ml — intensive emollient base for the body; hydrates, rebuilds the barrier, does not foster dependence. Learn more →
- Eczema Cream 50 ml — concentrated care for localised lesions in the maintenance phase. Learn more →
- Complete Eczema Programme — a full care system for more pronounced cases of atopy or eczema. Learn more →
Important reminder: EPIDERMA® dermocosmetics are not medicinal products and do not replace corticosteroid treatment in the acute phase of disease. They are intended as supportive care for the maintenance phase and for reducing the need for steroids over time — always in line with your dermatologist's recommendations.
When to see a doctor
Gradual steroid tapering can in many cases be managed with good barrier care and an informed approach. However, there are situations where a dermatology consultation is essential — do not delay if:
- The flare-up after stopping is significantly worse than your original condition before starting corticosteroid treatment.
- You experience burning of the skin (not itching), or redness spreading beyond the original affected areas.
- Your skin is weeping or peeling in sheets — signs of potential TSW.
- You have been using group III–IV corticosteroids (potent to very potent) for more than 4 weeks.
- The treatment involves a child.
- The steroid was applied to the face, eyelids, genitals, or skin folds — areas with higher absorption and increased risk of side effects.
In these cases, your dermatologist will assess whether switching to non-steroidal alternatives is appropriate (tacrolimus, pimecrolimus — TCI; crisaborol — PDE4 inhibitor; or, for more severe disease, biologic therapy).
Frequently asked questions
It depends on the duration and intensity of the previous steroid treatment. After short-term use (up to 4 weeks of a mild corticosteroid), the adjustment is relatively quick — 2–4 weeks. After long-term or intensive use, the gradual withdrawal phase may take 1–6 months. The key is consistent barrier care and patience.
In an acute, significant flare of eczema or psoriasis, corticosteroid treatment generally has no fast natural substitute — here the direct recommendation of a doctor applies. Natural dermocosmetics (ceramides, CBD, Betuldiol) are, however, ideal for the maintenance phase, supportive care, and reducing the frequency of steroid use. The non-steroidal approach works — but as a system, not as an emergency fix.
A rebound flare typically presents as a return of the original eczema — itching, redness in the areas where the steroid was applied. TSW is more intense: burning (not itching) dominates, redness spreads beyond the original lesions, the skin may weep and peel in sheets. If you are unsure, consult a dermatologist.
Mild worsening in the first days after reducing application frequency is normal and is not a reason to immediately return to daily use. If the worsening is significant or persists for more than 5–7 days, consult your dermatologist. The goal of the tapering plan is not zero at all costs — it is to find the minimum effective application frequency.
DermBalance Complex® is a dietary supplement designed to support skin from within — it contains zinc, vitamin D3, omega-3 fatty acids, probiotics, and hyaluronic acid. Zinc contributes to the maintenance of normal skin, and vitamin D3 supports normal immune function. As a complement to quality barrier dermocosmetics, it may support overall skin condition during the maintenance phase — it does not, however, replace medical care or corticosteroid treatment in the acute stage.
Scientific references
- Haeck IM et al. Educational paper on proactive therapy for atopic dermatitis. J Am Acad Dermatol, 2011; 64(1):199–201. PubMed: 21371772
- Schmitt J et al. Proactive therapy with topical corticosteroids or tacrolimus ointment for atopic eczema: a systematic review and meta-analysis. Br J Dermatol, 2011; 165(2):271–281. PubMed: 21901708
- van Zuuren EJ et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev, 2017; 2:CD012119. PubMed: 28864822
- Kono T et al. Clinical significance of the water retention and barrier function-improving capabilities of ceramide-containing formulations. J Dermatol, 2021; 48(11):1629–1638. PubMed: 34596254 | PMC: 9293121
- Kuzumi A et al. Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science. Biomolecules, 2025; 15(9):1219. PubMed: 41008526
- Wollenberg A et al. EADV guidelines for atopic eczema. J Eur Acad Dermatol Venereol, 2022; 36(9):1409–1431. PubMed: 35717106
This article is intended for educational purposes only and does not replace a dermatological consultation. Before starting or discontinuing any treatment, please consult your doctor.
Author: MUDr. Jiří Skalický